8.2 Psychosis, Schizophrenia & Acute Agitation
Key Takeaways
Schizophrenia diagnosis is anchored by Schneiderian first-rank symptoms (third-person auditory hallucinations, running commentary, thought alienation, passivity phenomena) persisting for ≥1 month.
Second-generation antipsychotics are first-line to minimize extrapyramidal side effects, though they necessitate metabolic surveillance for weight gain, dyslipidaemia, and hyperprolactinaemia (notably with risperidone).
Acute dystonic reactions require prompt anticholinergic therapy with procyclidine IM/IV, whereas tardive dyskinesia is worsened by anticholinergics and requires medication review and potential transition to clozapine.
Clozapine is uniquely indicated for treatment-resistant schizophrenia (failure of ≥2 adequate trials) and carries a mandatory hematological monitoring protocol due to the life-threatening risk of agranulocytosis.
Neuroleptic malignant syndrome (NMS) presents with hyperthermia, 'lead-pipe' rigidity, autonomic storm, and marked CK elevation; management requires stopping antipsychotics, aggressive cooling, and bromocriptine or dantrolene.
Psychosis, Schizophrenia & Acute Agitation
In accordance with NICE clinical guideline CG178 (Psychosis and schizophrenia in adults), psychotic disorders are characterized by a loss of contact with reality, manifesting through abnormalities in perception, belief, and behavioral organization. Core clinical competencies include recognizing Schneiderian first-rank symptoms, managing antipsychotic adverse effects, adhering to mandatory monitoring registers in treatment resistance, and executing rapid tranquillisation safely.
Clinical Phenomenology of Schizophrenia & First-Rank Symptoms
Under ICD-11 and DSM-5, schizophrenia requires continuous disturbance for at least 1 month (with functional decline persisting for 6 months under DSM-5). Organic causes (cannabis/stimulant intoxication, anti-NMDA receptor encephalitis, Wilson's disease, SLE, temporal lobe epilepsy) must be rigorously excluded.
Kurt Schneider's First-Rank Symptoms (FRS)
- Auditory Hallucinations:
- Third-person voices: Voices conversing or arguing about the patient ("He shouldn't do that").
- Running commentary: Voices narrating the patient's ongoing actions in real-time.
- Thought echo (Gedankenlautwerden): The patient hears their own thoughts spoken aloud.
- Delusional Perception: A normal real-world sensory perception is instantaneously linked to an abnormal, private delusional meaning (e.g., seeing a green traffic light and knowing one is chosen to lead the nation).
- Thought Alienation (Passivity of Thought):
- Thought insertion: Unshakeable conviction that alien thoughts are placed into one's mind from outside.
- Thought withdrawal: Belief that thoughts are being removed or stolen from one's mind.
- Thought broadcast: Belief that thoughts are radiating outwardly and heard by others.
- Passivity Phenomena (Delusions of Control):
- Experiences where emotions (made affect), impulses (made impulse), or actions (made volition) are controlled by an external force.
- Somatic passivity: Bodily sensations experienced as being inflicted by an outside entity.
Positive vs Negative Symptoms
- Positive Symptoms (Mesolimbic Hyperdopaminergia): Delusions, hallucinations, and formal thought disorder (tangentiality, derailment, neologisms, word salad).
- Negative Symptoms (Mesocortical Hypodopaminergia): The 5 As: Avolition (lack of drive), Anhedonia, Alogia (poverty of speech), Affective flattening (blunted affect), and Asociality (social withdrawal).
Antipsychotic Pharmacotherapy: FGAs vs SGAs
- First-Generation Antipsychotics (FGAs e.g., Haloperidol, Chlorpromazine, Flupentixol):
- Mechanism: Potent antagonism of dopamine D2 receptors in the mesolimbic tract. High D2 blockade in the nigrostriatal tract causes marked Extrapyramidal Side Effects (EPSEs); blockade in the tuberoinfundibular tract causes hyperprolactinaemia.
- Second-Generation Antipsychotics (SGAs e.g., Olanzapine, Risperidone, Quetiapine, Aripiprazole):
- Mechanism: Dual 5-HT2A and D2 receptor antagonism (Aripiprazole is a partial D2 agonist). Reduced EPSE risk, but substantial metabolic syndrome liability (weight gain, dyslipidaemia, impaired fasting glucose, new-onset type 2 diabetes).
- Drug Profiles:
- Olanzapine: Highest risk of weight gain and metabolic syndrome (monitor HbA1c, lipids, BMI).
- Risperidone: Potent tuberoinfundibular D2 blockade causing pronounced hyperprolactinaemia (galactorrhoea, amenorrhoea, gynaecomastia, sexual dysfunction, osteopenia).
- Aripiprazole: Partial D2 agonist; metabolically neutral, weight-neutral, and prolactin-sparing.
- Quetiapine: Very low striatal D2 affinity; lowest EPSE risk (preferred in Parkinson's disease psychosis), but sedating.
Extrapyramidal Side Effects (EPSEs): Classification & Management
| EPSE Category | Clinical Onset | Characteristic Signs & Symptoms | Pathophysiological Mechanism | Clinical Management |
|---|---|---|---|---|
| Acute Dystonia | Hours to days | Involuntary sustained painful muscle spasms: oculogyric crisis (upward eye deviation), torticollis (neck torsion), trismus (jaw clench), laryngeal spasm | Acute striatal dopamine-acetylcholine imbalance producing relative cholinergic excess | Procyclidine 5–10 mg IM or IV (or Benzatropine); provides rapid relief within minutes. |
| Akathisia | Days to weeks | Intense subjective inner motor restlessness, inability to sit still, continuous pacing, severe distress | Nigrostriatal and mesocortical dopamine blockade | Reduce dose; switch to quetiapine/aripiprazole; first-line medical therapy: Propranolol 10–40 mg TDS or low-dose Lorazepam. |
| Drug-Induced Parkinsonism | Weeks to months | Triad of tremor (resting pill-rolling), rigidity (cogwheel/lead-pipe), and bradykinesia (festinating gait, masked facies) | Nigrostriatal dopamine D2 depletion | Reduce dose; switch to SGA; add oral anticholinergic (Procyclidine 2.5–5 mg TDS). Avoid indefinite anticholinergics. |
| Tardive Dyskinesia (TD) | Months to years | Involuntary choreoathetoid movements: orofacial dyskinesia (lip-smacking, tongue protrusion ["fly-catcher tongue"], chewing motions), chorea of limbs | Chronic D2 blockade causing striatal dopamine receptor upregulation and supersensitivity | Discontinue anticholinergics immediately (anticholinergics worsen TD!). Reduce antipsychotic; switch to Clozapine; consider VMAT2 inhibitors (Valbenazine). |
Treatment-Resistant Schizophrenia & Clozapine Protocols
- Treatment-Resistant Schizophrenia (TRS): Lack of symptomatic remission despite at least two adequate trials of different antipsychotics (each for ≥6–8 weeks at therapeutic doses), with at least one being an SGA.
- Clozapine Indication: The only evidence-based antipsychotic for TRS; uniquely reduces suicide and persistent aggression in schizophrenia.
Caution
Agranulocytosis Risk & FBC Protocol: Clozapine carries a 1% risk of life-threatening agranulocytosis. Mandatory central monitoring (CPMS/ZTAS) requires FBC monitoring: weekly for weeks 1–18, fortnightly for weeks 19–52, then monthly thereafter.
- Mandatory Stop Rule: Stop clozapine immediately and permanently if Absolute Neutrophil Count (ANC) < 1.5 x 10^9/L OR White Cell Count (WCC) < 3.0 x 10^9/L. Never rechallenge. Admit for protective reverse barrier isolation and IV broad-spectrum antibiotics for neutropenic sepsis.
Other Critical Clozapine Toxicities
- Severe Constipation / Paralytic Ileus: Potent anticholinergic/antiserotonergic gut hypomotility; leading cause of clozapine-related death. Prescribe routine prophylactic laxatives (senna, docusate).
- Myocarditis & Cardiomyopathy: Most common within first 2 months; monitor troponin, CRP, and baseline echocardiogram. Discontinue if myocarditis develops.
- Hypersalivation (Sialorrhoea): Treat with sublingual ipratropium spray or oral hyoscine.
- Seizures: Dose-dependent; manage with sodium valproate (avoid carbamazepine due to bone marrow suppression).
Neuroleptic Malignant Syndrome (NMS): Diagnosis & Emergency Management
An idiosyncratic, life-threatening complication of dopamine D2 antagonists (or sudden L-Dopa withdrawal).
Cardinal Tetrad & Investigations
- Severe "Lead-Pipe" Muscle Rigidity
- Hyperthermia (>38.0°C, often >40°C)
- Autonomic Instability (profuse sweating, tachycardia, tachypnoea, labile BP)
- Altered Mental Status (confusion, catatonia, stupor, coma)
- Investigations: Marked Creatine Kinase elevation (CK > 1000 IU/L, frequently >10,000–50,000 IU/L) from rhabdomyolysis, leukocytosis (15–30 x 10^9/L), acute renal failure (myoglobinuria), and metabolic acidosis.
Diagnostic Comparison: NMS vs Serotonin Syndrome
| Feature | Neuroleptic Malignant Syndrome (NMS) | Serotonin Syndrome (SS) |
|---|---|---|
| Offending Drugs | Dopamine D2 antagonists (haloperidol, olanzapine) or L-Dopa withdrawal | Serotonergic combinations (SSRI + MAOI, tramadol, linezolid, triptans) |
| Onset | Subacute: days to weeks (typically 3–9 days) | Hyperacute: hours (typically 6–24 hours) |
| Neuromuscular Signs | Severe generalized "lead-pipe" rigidity, hyporeflexia | Neuromuscular hyperactivity: spontaneous clonus, ocular clonus, hyperreflexia, tremor |
| Pupils & Bowel | Normal pupils; normal or reduced bowel sounds | Mydriasis (dilated pupils); hyperactive bowel sounds, diarrhoea |
| Creatine Kinase | Massively elevated (>10,000 IU/L) | Normal or mildly elevated |
| Specific Medical Therapy | Bromocriptine (dopamine agonist) or Dantrolene (muscle relaxant) | Cyproheptadine (5-HT2A antagonist) |
Emergency Management Protocol
- Stop all antipsychotics immediately; admit to ICU/HDU.
- Aggressive IV fluid resuscitation with 0.9% normal saline (maintaining urine output >100–200 mL/h to prevent acute renal failure from myoglobinuria).
- Active external cooling (cooling blankets, ice packs).
- IV benzodiazepines (lorazepam) for agitation and rigidity.
- Specific medical therapy: Bromocriptine (dopamine agonist 2.5–5 mg TDS) or Dantrolene sodium (muscle relaxant 1–2.5 mg/kg IV bolus).
Acute Behavioural Disturbance & Rapid Tranquillisation
- Stepwise De-escalation: Verbal engagement, low-stimulus room, offering food/drink.
- Oral Medication (First-Line): Oral lorazepam (1–2 mg) OR oral haloperidol (2–5 mg) OR oral olanzapine (5–10 mg).
- Intramuscular Rapid Tranquillisation (Parenteral): Indicated only if oral medication is refused and imminent risk of serious physical injury exists.
- IM Lorazepam 1 to 2 mg OR
- IM Haloperidol 2 to 5 mg PLUS IM Promethazine 25 to 50 mg (promethazine sedates and prevents acute dystonias).
Warning
Rapid Tranquillisation Safety Rules:
- Baseline ECG Mandatory for Haloperidol: Haloperidol prolongs the QTc interval (risk of torsades de pointes). Use IM lorazepam if an ECG cannot be obtained.
- NEVER Combine IM Olanzapine and IM Benzodiazepines: Co-administration within 1 hour carries a risk of fatal cardiorespiratory arrest and severe hypotension.
- Post-Sedation Monitoring: Monitor respiratory rate, SpO2, pulse, and BP every 15 minutes for 1 hour, then hourly. Ensure flumazenil and resuscitation equipment are accessible.
Other Psychotic Disorders
- Delusional disorder: persistent, often well-systematised delusions (for example persecutory, jealous or somatic) for at least 1 month (DSM-5; 3 months in ICD-11), without the other features of schizophrenia, and with relatively preserved functioning. Antipsychotics and psychological approaches are used, although insight is usually poor.
- Schizoaffective disorder: symptoms of schizophrenia occur together with a major mood episode (manic or depressive) in the same episode of illness, with psychotic symptoms also present without mood symptoms at times. Management combines an antipsychotic with mood stabilisers or antidepressants as needed.
- Substance-induced psychosis (cannabis, stimulants, alcohol withdrawal) and organic causes (delirium, temporal lobe epilepsy, autoimmune encephalitis, steroids) should be excluded in every first episode.
A 22-year-old university student is admitted to the psychiatric inpatient assessment unit with a first acute episode of schizophrenia. He is initiated on oral haloperidol 5 mg once daily. Approximately 18 hours after receiving his first dose, nursing staff urgently bleep the on-call doctor because the patient is in severe distress. On examination, his neck is painfully hyperextended and twisted to the right (spasmodic torticollis), his jaw is clamped shut (trismus), and his eyes are involuntarily deviated upward toward the ceiling (oculogyric crisis). He is conscious, highly anxious, and unable to speak clearly. What is the clinical diagnosis and the most appropriate immediate medical intervention?
Conversion disorder; offer firm reassurance and structured behavioral therapy
Akathisia; administer oral propranolol 40 mg immediately
Tardive dyskinesia; administer oral clozapine 25 mg immediately
Acute dystonia; give IM or IV procyclidine 5–10 mg immediately
A 36-year-old man with treatment-resistant schizophrenia has been taking oral clozapine for 7 months. His symptoms have shown substantial improvement, and he is attending outpatient psychiatric follow-up. Today he attends his local urgent care centre complaining of a 2-day history of high fever, severe sore throat, painful swallowing, and painful oral mucosal ulceration. His temperature is 38.6°C, heart rate is 108 bpm, and blood pressure is 118/76 mmHg. Pharyngeal examination reveals severe erythema with white exudates and several deep aphthous ulcers on the tongue and buccal mucosa. An urgent full blood count demonstrates: total white cell count (WCC) 2.2 x 10^9/L (normal range 4.0–11.0 x 10^9/L), absolute neutrophil count (ANC) 0.8 x 10^9/L (normal range 1.5–7.0 x 10^9/L), and platelet count 240 x 10^9/L. What is the most appropriate immediate management?
Increase clozapine dose to treat exacerbation of psychotic stress, administer subcutaneous filgrastim (G-CSF), and discharge with GP follow-up
Stop clozapine permanently, admit for isolation, IV antibiotics and urgent haematology input
Withhold clozapine temporarily, start oral fluconazole for oral candidiasis, and resume clozapine once symptoms resolve
Continue clozapine at a reduced dose, prescribe oral amoxicillin, and repeat the full blood count in 48 hours
A 31-year-old man with chronic paranoid schizophrenia has his dose of intramuscular flupentixol decanoate increased, alongside the addition of oral haloperidol 10 mg daily for acute auditory hallucinations. Four days later, he is brought to the emergency department in an obtunded state. On arrival, he is stuporous, severely diaphoretic, and tachypnoeic. Physical examination reveals generalized severe 'lead-pipe' muscle rigidity and intermittent cogwheel resistance throughout both upper and lower limbs. His vital signs are: temperature 39.8°C, heart rate 132 bpm, blood pressure 184/110 mmHg, respiratory rate 28 breaths/min, and SpO2 94% on room air. Laboratory tests reveal: serum creatine kinase (CK) 34,500 IU/L (normal range 40–320 IU/L), white cell count 18.2 x 10^9/L, urea 16.2 mmol/L, and creatinine 188 µmol/L. Urinalysis shows 4+ blood on dipstick with no red blood cells on microscopy. What is the diagnosis, and which pair of specific pharmacological agents can be utilized in the medical management of this condition?
Neuroleptic malignant syndrome; managed with bromocriptine and dantrolene sodium
Serotonin syndrome; managed with intravenous cyproheptadine and esmolol
Acute rhabdomyolysis secondary to cocaine intoxication; managed with intravenous sodium valproate and naloxone
Malignant catatonia; managed with high-dose intravenous haloperidol and procyclidine
Sections you finish are checked off in the contents.